These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

871 related articles for article (PubMed ID: 31278395)

  • 1. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
    Linehan WM; Ricketts CJ
    Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
    Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R; Bottaro DP; Choueiri TK; Gibbs RA; Godwin AK; Haake S; Hakimi AA; Henske EP; Hsieh JJ; Ho TH; Kanchi RS; Krishnan B; Kwiatkowski DJ; Liu W; Merino MJ; Mills GB; Myers J; Nickerson ML; Reuter VE; Schmidt LS; Shelley CS; Shen H; Shuch B; Signoretti S; Srinivasan R; Tamboli P; Thomas G; Vincent BG; Vocke CD; Wheeler DA; Yang L; Kim WY; Robertson AG; ; Spellman PT; Rathmell WK; Linehan WM
    Cell Rep; 2018 Apr; 23(1):313-326.e5. PubMed ID: 29617669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
    Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and clinical value of SALL4 in renal cell carcinomas.
    Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
    Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
    Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
    Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
    Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
    Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms.
    Skala SL; Wang X; Zhang Y; Mannan R; Wang L; Narayanan SP; Vats P; Su F; Chen J; Cao X; Siddiqui J; Argani P; Cieślik MP; Giordano TJ; Chinnaiyan AM; Dhanasekaran SM; Mehra R
    Eur Urol; 2020 Jul; 78(1):63-74. PubMed ID: 32299640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel biomarkers to distinguish clear cell and non-clear cell renal cell carcinoma using bioinformatics and machine learning.
    Panwoon C; Seubwai W; Thanee M; Sangkhamanon S
    PLoS One; 2024; 19(6):e0305252. PubMed ID: 38857246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
    Zhao H; Leppert JT; Peehl DM
    PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
    Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
    Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of CT, MRI imaging features of renal cell carcinoma with different histopathological types.
    Wang X; Kong W; Wang Y; Wang Y; Chen Y; Shi Z; Liu Y
    J BUON; 2021; 26(5):2053-2058. PubMed ID: 34761616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of subtypes of metastatic renal-cell carcinoma: correlating findings of fine-needle aspiration biopsy and surgical pathology.
    Mai KT; Alhalouly T; Lamba M; Yazdi HM; Stinson WA
    Diagn Cytopathol; 2003 Feb; 28(2):66-70. PubMed ID: 12561022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
    Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
    Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.
    Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM
    J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.